Transthyretin amyloidosis (ATTR) is a progressive disorder caused by misfolded transthyretin proteins depositing in tissues, impairing organ function. The treatment market for this rare disease is rapidly expanding, driven by heightened disease recognition and innovative therapeutics, valued at over USD 1 billion according to GlobalData. Request FREE sample copy of the report "Global... https://www.metatechinsights.com/industry-insights/transthyretin-amyloidosis-treatment-market-2259